
Polatuzumab vedotin – A potent ADC in NHL

Michael Wenger, M.D.

Senior Group Medical Director

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1 pricing and product initiatives of competitors;
- 2 legislative and regulatory developments and economic conditions;
- 3 delay or inability in obtaining regulatory approvals or bringing products to market;
- 4 fluctuations in currency exchange rates and general financial market conditions;
- 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
- 6 increased government pricing pressures;
- 7 interruptions in production;
- 8 loss of or inability to obtain adequate protection for intellectual property rights;
- 9 litigation;
- 10 loss of key executives or other employees; and
- 11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

All mentioned trademarks are legally protected.

Introduction: Polatuzumab vedotin


Polatuzumab vedotin in 1L DLBCL

Polatuzumab vedotin in R/R FL/DLBCL

Polatuzumab vedotin development program

MoA: Polatuzumab vedotin (anti-CD79b ADC)

Potential to become part of a future backbone



Product profile

- ADC designed for targeting microtubule inhibitor MMAE to cells expressing CD79b
- Linker is stable in the bloodstream but releases the drug payload inside the target cell

Introduction: Polatuzumab vedotin

Polatuzumab vedotin in 1L DLBCL

Polatuzumab vedotin in R/R FL/DLBCL


Polatuzumab vedotin development program

Polatuzumab + Rituxan-CHP in 1L DLBCL

Early efficacy and safety data



Study design




Phase Ib/II results

- Phase 2 dose of 1.8 mg/kg established
- Safety profile is inline with R-CHOP
- CR of 70% and PR of 15% achieved
- Efficacy promising as patients treated in the dose-expansion were strongly weighted in the high-risk category by the IPI

End of treatment responses by PET-CT

	Pola + Rituxan-CHP	
	Pola < 1.8 mg/kg (n=5)	Pola 1.8 mg/kg (n=33)
CR, n (%)	4 (80)	23 (70)
PR, n (%)	1 (20)	5 (15)
PD, n (%)	0	3 (9)
Not evaluable, n (%)	0	2 (6)

Duration of response



Introduction: Polatuzumab vedotin

Polatuzumab vedotin in 1L DLBCL

Polatuzumab vedotin in R/R FL/DLBCL

Polatuzumab vedotin development program

Introduction: Polatuzumab vedotin

Polatuzumab vedotin in 1L DLBCL

Polatuzumab vedotin in R/R FL/DLBCL

Polatuzumab vedotin development program

Development program in NHL



Polatuzumab vedotin trials in FL and DLBCL

	NHL				Ph1	Ph2	Ph3	
	Compound	Combination	Study name	Indication				
	Gazyva	+bendamustine	<i>GADOLIN</i>	FL (iNHL) (Rituxan refractory)	██████████	██████████	██████████	✓
	Gazyva	+CHOP	<i>GOYA</i>	1L DLBCL (aNHL)	██████████	██████████	██████████	✗
	Gazyva	+chemo	<i>GALLIUM</i>	1L FL (iNHL)	██████████	██████████	██████████	✓
	Venclexta*	+Rituxan/+Rituxan +bendamustine	<i>CONTRALTO</i>	R/R FL (iNHL)	██████████	██████████	██████████	
	Venclexta	+Rituxan +CHOP	<i>CAVALLI</i>	1L DLBCL (aNHL)	██████████	██████████	██████████	
	Venclexta	+Rituxan +bendamustine		R/R NHL	██████████	██████████	██████████	
	Venclexta			R/R CLL and R/R NHL	██████████	██████████	██████████	
	Venclexta	+Gazyva/Rituxan+polatuzumab		R/R DLBCL (aNHL) and R/R FL (iNHL)	██████████	██████████	██████████	
	polatuzumab	+Rituxan/Gazyva	<i>ROMULUS</i>	R/R DLBCL (aNHL) and R/R FL (iNHL)	██████████	██████████	██████████	ASH
	polatuzumab	+Gazyva/Rituxan+bendamustin		R/R DLBCL (aNHL) and R/R FL (iNHL)	██████████	██████████	██████████	ASH
	polatuzumab	+Gazyva+CHP/Rituxan+CHP		1L DLBCL (aNHL)	██████████	██████████	██████████	ASH
	polatuzumab	+Gazyva/Rituxan+lenalidomide		R/R DLBCL (aNHL) and R/R FL (iNHL)	██████████	██████████	██████████	
	Tecentriq	+Gazyva or +tazemetostat1**		R/R DLBCL (aNHL) and R/R FL (iNHL)	██████████	██████████	██████████	
	Tecentriq	+Gazyva+lenalidomide		R/R FL (iNHL)	██████████	██████████	██████████	
	Tecentriq	+Gazyva/Rituxan+benda or CHOP		1L FL (iNHL) and 1L DLBCL (aNHL)	██████████	██████████	██████████	
	Tecentriq	+Gazyva/Rituxan+polatuzumab		R/R DLBCL (aNHL) and R/R FL (iNHL)	██████████	██████████	██████████	
	idasanutlin	+Gazyva/Rituxan		R/R DLBCL (aNHL) and R/R FL (iNHL)	██████████	██████████	██████████	
	undisclosed ADC			R/R NHL	██████████	██████████	██████████	

iNHL=indolent non-hodgkin's lymphoma; aNHL=agressive NHL; DLBCL=diffuse large B cell lymphoma; FL=follicular lymphoma; CHOP=cyclophosphamide, doxorubicin, vincristine and prednison; * Venclexta in collaboration with AbbVie; Gazyva in collaboration with Biogen; polatuzumab vedotin in collaboration with Seattle Genetics; **External collaboration; ADC=antibody drug conjugate

Doing now what patients need next